



Genzyme Australasia Pty Ltd  
ABN 24 083 420 526

Level 1, Building C  
12-24 Talavera Road  
North Ryde NSW 2113, Australia  
Tel : +61 2 9978 3900  
Fax : +61 2 98893900

14 December 2009

Address

Dear Sir/Madam

**RE: Important Update Regarding New Supply of Fabrazyme® (agalsidase beta)**

Thank you for all that you have done over the last few months during the Fabrazyme supply constraint period. We have received feedback from many of you that this has been a very difficult time and please know that we are working very hard to improve the situation.

We are writing to update you on the anticipated availability of Fabrazyme as of January 2010. As you are aware, beginning on June 1, 2009, Genzyme reduced shipments of Fabrazyme of regular use in order to manage supply during the current product shortage. This shortage resulted from the temporary suspension of bulk production at our Allston Landing manufacturing facility while Genzyme completed a comprehensive sanitation process.

The sanitation process is complete and bioreactors used to produce Fabrazyme have been operational since August. However, the output of Fabrazyme has remained at the low end of our historical manufacturing experience, placing continued constraints on supply going forward. This low output is not related to the Vesivirus contamination that was identified in our Allston facility in June 2009. No further indication of Vesivirus contamination has been observed in any Genzyme facility to date.

Due to the temporary interruption of fill/finish operations for maintenance at Allston and ongoing low manufacturing productivity Genzyme currently expects to continue shipping Fabrazyme at the current 30% of underlying demand through March of 2010. As you will be aware the Life Saving Drugs Program (LSDP) and the Fabry Disease Advisory Committee has, and will continue to implement strategies in an effort to avoid a complete depletion of Fabrazyme supply during the period of Fabrazyme shortage

Genzyme plans to resume shipping Fabrazyme at 70 – 100% of full dose for existing patients beginning in the second quarter of 2010. The range and timing depends on restarting fill/finish for Fabrazyme at the Allston facility and on restoring the overall productivity of Fabrazyme manufacturing.

It is important that during this time of temporary dose reductions, you stay in contact with your treating physician, who will continue to monitor you so that any deterioration in disease severity can be detected early and to make individual treatment decisions.

As we have previously communicated, Genzyme has received reports of foreign particles observed in some products filled at the Allston Landing facility. In order to ensure that patients are not exposed to foreign particles during product

administration, we have sent notification to alert health care practitioners of the potential presence of such foreign particles. Genzyme has also reinforced the existing recommendations contained in the Australian approved Product Information for the preparation and administration of Fabrazyme for visual inspection and the use of an in-line filter during your infusion. These recommendations will minimise the risk of exposure to foreign particles during your treatment. Foreign particles are not uncommon in injectable products.

Please note that this information is unrelated to the decontamination of the Allston Landing facility.


Please speak to your treating physicians/pharmacists for information about the potential risks to patients.

We recognise the significant challenges that the limited availability of Fabrazyme has created for you, your family members and caregivers, and we appreciate all that you have done throughout the year to help manage through this disruption. We are working diligently to improve our ability to supply your long-term needs.

We anticipate providing further updates to the Fabry community in February 2010. We will also notify the Fabry community when the Fabrazyme supply becomes adequate for new patients to begin treatment. For more information or to discuss any concerns, please contact the LSDP at (02) 6289 2314 or [lsdp@health.gov.au](mailto:lsdp@health.gov.au).

On behalf of everyone at Genzyme, thank you for your continued understanding and support as we work to reinstate full supply.

Yours sincerely,

A handwritten signature in blue ink, appearing to read 'Katy Williams Day', with a large checkmark at the end.

Katy Williams Day  
Director, Regulatory and Scientific Affairs